

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-15. (Canceled)

1 16. (2X Amended) A pharmaceutical composition comprising at least one HPV  
16 L1ΔE7<sub>1-55</sub> fusion protein ~~from at least one L1 protein of one or more papillomaviruses and~~  
~~at least one C terminally deleted E7 protein, wherein about 38 to about 43 amino acids are~~  
~~deleted, of one or more papillomaviruses,~~ wherein the fusion protein contains no  
papillomavirus-unspecific epitopes and wherein the pharmaceutical composition is capable of  
preventing or treating human papillomavirus (HPV)-specific tumour.

3 17. (Previously Presented) The pharmaceutical composition according to claim  
1 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.

4 18. (Previously Presented) The pharmaceutical composition according to claim  
1 16, wherein the pharmaceutical composition contains no adjuvant.

5 19. (Previously Presented) The pharmaceutical composition according to claim  
1 16, wherein the pharmaceutical composition comprises suitable additives and/or excipients.

6 20. (Previously Presented) The pharmaceutical composition according to claim  
5 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about  
7.3 to about 7.45.

11 21. (Previously Presented) The pharmaceutical composition according to claim  
6 20, wherein the salt is an alkali metal or alkaline earth metal salt.

15 22. (Previously Presented) The pharmaceutical composition according to claim  
6 20, wherein the pH is adjusted using a buffer.

23.-28. (Canceled)

<sup>2</sup> ~~29~~. (2X Amended) The pharmaceutical composition according to claim <sup>1</sup> ~~16~~, wherein ~~font~~ the fusion protein is present in the form of a capsid and/or capsomer.

30.-31. (Canceled)

<sup>6</sup> <sup>7</sup> ~~32~~. (Previously Presented) The pharmaceutical composition according to claim ~~20~~, wherein the additive or excipient is 0.4 to about 3 M of a salt having a pH of about 7.3 to about 7.45.

<sup>6</sup> <sup>8</sup> ~~33~~. (Previously Presented) The pharmaceutical composition according to claim ~~20~~, wherein the additive or excipient is 0.5 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

<sup>6</sup> <sup>9</sup> ~~34~~. (Previously Presented) The pharmaceutical composition according to claim ~~20~~, wherein the additive or excipient is 1 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

<sup>10</sup> ~~35~~. (2X Amended) The pharmaceutical composition according to claim <sup>6</sup> ~~20~~, wherein the salt has a pH of ~~74~~ 7.4.

<sup>11</sup> <sup>12</sup> ~~36~~. (Previously Presented) The pharmaceutical composition according to claim ~~21~~, wherein the salt is a halide or a phosphate.

<sup>11</sup> <sup>13</sup> ~~37~~. (Previously Presented) The pharmaceutical composition according to claim ~~21~~, wherein the salt is an alkali metal halide.

<sup>11</sup> <sup>14</sup> ~~38~~. (Previously Presented) The pharmaceutical composition according to claim ~~21~~, wherein the salt is NaCl and/or KCl.

<sup>15</sup> <sup>16</sup> ~~39~~. (Previously Presented) The pharmaceutical composition according to claim ~~22~~, wherein the pH is adjusted using a phosphate buffer, tris buffer, HEPES buffer or MOPS buffer.

40.-63. (Canceled)

17 64. (Amended) A method for producing a pharmaceutical composition comprising combining at least one ~~fusion protein from at least one L1 protein of one or more papillomaviruses and at least one C terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses, wherein the fusion protein contains no papillomavirus unspecific epitopes~~ HPV 16 L1ΔE7<sub>1-55</sub> fusion protein <sup>of claim 16</sup> together with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition, said pharmaceutical composition being capable of preventing or treating human papillomavirus (HPV)-specific tumour.

18 65. (Previously Presented) A method for preventing or treating human papillomavirus (HPV)-specific tumour, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 16.

66. (Canceled)